ESC 365 - Panel discussion and summary - Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death.

HFA Premium Access

Panel discussion and summary - Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death.

Session: Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death

Topic: Treatment

Speaker: Professor C. Leclercq (Rennes, FR)

Sponsored by Zoll

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Professor Christophe Leclercq

Hospital Pontchaillou of Rennes, Rennes (France)

60 presentations

10 followers

4 more presentations in this session

Introduction - Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death

Speaker: Professor L. Kober (Copenhagen, DK)

Distilling the clinical evidence behind the WCD - What have clinical trials and registries told us?

Speaker: Professor C. Veltmann (Bremen, DE)

Taking your time in the treatment of newly diagnosed heart failure patients.

Speaker: Doctor J. Erath (Frankfurt, DE)

The impact of the WCD for patients who choose to wear it.

Speaker: Professor A. Flammer (Zurich, CH)

Access the full session

Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death

Speakers: Professor C. Leclercq, Professor L. Kober, Professor C. Veltmann, Doctor J. Erath, Professor A. Flammer

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources